Basic Study

Fibroblast-derived CXCL12/SDF-1α promotes CXCL6 secretion and co-operatively enhances metastatic potential through the PI3K/Akt/mTOR pathway in colon cancer

Jia-Chi Ma, Xiao-Wen Sun, He Su, Quan Chen, Tian-Kang Guo, Yuan Li, Xiao-Chang Chen, Jin Guo, Zhen-Qiang Gong, Xiao-Dan Zhao, Jian-Bo Qi

Author contributions: Ma JC and Sun XW contributed equally to this article; Su H, Chen Q and Guo TK conceived and designed the study; Li Y, Chen XC, Gong ZQ, Zhao XD and Qi JB performed the experiments; Ma JC, Su H, Chen Q, Chen XC, Guo J and Gong ZQ analyzed and interpreted the data; Ma JC and Sun XW drafted the manuscript.

Supported by National Natural Science Foundation of China, No. 81260325 (to Ma JC).

Conflict-of-interest statement: The authors declare that they have no competing interests.

Data sharing statement: No additional unpublished data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Abstract

AIM
To investigate the underlying mechanism by which CXCL12 and CXCL6 influences the metastatic potential of colon cancer and internal relation of colon cancer and stromal cells.

METHODS
Western blotting was used to detect the expression of CXCL12 and CXCL6 in colon cancer cells and stromal cells. The co-operative effects of CXCL12 and CXCL6 on proliferation and invasion of colon cancer cells and human umbilical vein endothelial cells (HUVECs) were determined by enzyme-linked immunosorobent assay, and proliferation and invasion assays. The angiogenesis of HUVECs through interaction with cancer cells and stromal cells was examined by angiogenesis assay. We eventually investigated activation of PI3K/Akt/mTOR signaling by CXCL12 involved in the metastatic process of colon cancer.
RESULTS
CXCL12 was expressed in DLD-1 cancer cells and fibroblasts. The secretion level of CXCL6 by colon cancer cells and HUVECs were significantly promoted by fibroblasts derived from CXCL12. CXCL6 and CXCL2 could significantly enhance HUVEC proliferation and migration \( (P < 0.01) \). CXCL6 and CXCL2 enhanced angiogenesis by HUVECs when cultured with fibroblast cells and colon cancer cells \( (P < 0.01) \). CXCL12 also enhanced the invasion of colon cancer cells. Stromal cell-derived CXCL12 promoted the secretion level of CXCL6 and co-operatively promoted metastasis of colon carcinoma through activation of the PI3K/Akt/mTOR pathway.

CONCLUSION
Fibroblast-derived CXCL12 enhanced the CXCL6 secretion of colon cancer cells, and both CXCL12 and CXCL6 co-operatively regulated the metastasis via the PI3K/Akt/mTOR signaling pathway. Blocking this pathway may be a potential anti-metastatic therapeutic target for patients with colon cancer.

Key words: CXCL12/SDF-1α; CXCL6; Metastasis; PI3K/Akt/mTOR pathway; Colon cancer

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: This study has provided the first report of fibroblast-derived CXCL12 enhancement of CXCL6 secretion in colon cancer cells, and both CXCL12 and CXCL6 co-operatively regulating metastasis through the PI3K/Akt/mTOR signaling pathway. Blockage of this pathway may be a potential anti-metastatic therapeutic target for patients with colon cancer. Our work might encourage further investigation into more potent angiogenesismodulating agents to improve the effectiveness of colon cancer therapies.

INTRODUCTION
Colon cancer is the fourth most frequently diagnosed cancer in the United States. In 2015, an estimated 93,090 new cases of colon cancer occurred in the United States. During that same year, it was estimated that 49,700 patients died from colon and rectal cancers. The poor prognosis of colon cancer is attributable to its tendency of metastases. However, the precise mechanisms that determine the directional proliferation and invasion of cancer cells into specific organs remain to be established. Therefore, exploring the fundamental mechanism of invasion, proliferation, metastasis and tumor biological behaviors at the level of cellular or molecular microenvironments is needed in clinical diagnosis and therapy.

Chemokines (chemotactic cytokines) form a complex family of small, secreted proteins that play an important role in innate and adaptive immunity, homeostatic processes, angiogenesis and tumorigenesis. Based upon the position of conserved cysteine residues, chemokines are classified into four subfamilies (C, CC, CXC, CX3C). CXC chemokines have been proven to modulate tumor behaviors, especially in regulation of angiogenesis, activation of a tumor-specific immune response and stimulation of tumor cell proliferation in an autocrine or paracrine fashion. However, updated research has shed new light on this subfamily of cytokines, indicating that its members have multifaceted roles in the microenvironment that consists of the tumor cells themselves and/or stromal cells, including infiltrating leukocytes, endothelial cells (ECs) and fibroblasts.

The functions of CXC chemokines in the tumor microenvironment depend considerably on the chemokine type and tumor and stromal cells’ characteristics. In addition, there are cases in which chemokines have been implicated as having tumor-inhibiting gene activities, and there are many more examples of CXC chemokines with tumor-promoting roles. Two of the most famous members are the stromal cell-derived factor-1 (SDF-1/CXCL12/IL12) and chemokine ligand 6 (CXCL6). Numerous studies have shown that their activities would increase the establishment of tumorigenesis, invasion, proliferation and metastases.

Recent analysis has shown that CXCL12 supports the survival or growth of a variety of normal or malignant cell types, including hematopoietic progenitors, germ cells, leukemia B cells and breast carcinoma cells. Other studies have shown that the CXCL12/CXCR4 and related axis are involved in tumor metastasis to sites which are characterized by high production of CXCL12, such as liver, lung and bone marrow. Activation of the CXCL12/CXCR4 signaling axis leads to chemotaxis, cell survival, and/or proliferation; however, the downstream signaling cascades are tissue-specific and not well characterized.

CXCL6, a small cytokine belonging to the CXC chemokine family, is also known as granulocyte chemotactic protein 2. As its former name suggests, CXCL6 is a chemoattractant for neutrophilic granulocytes. It elicits its chemotactic effects by interacting with the chemokine receptors CXCR1 and CXCR2. This tumor progression may occur as a function of the regulation of angiogenesis, cell motility, immune cell infiltration, cell growth and survival in the microenvironment, and modulation of local anti-
tumor immune responses\(^{(19)}\). As evidenced by various experiments, CXCL6 is over expressed in colorectal, breast, lung and thyroid cancers. Actions of tumor cells in the microenvironment were also regulated by complicated molecular mechanisms\(^{(20-23)}\).

Different chemokines played their specific roles. Both the angiogenesis-promoting effect of CXCL6 and chemotactic effect of CXCL12 play important roles in tumorigenesis and metastasis\(^{(24,25)}\). However, the molecular mechanisms of the active signaling pathway by which CXCL12 and CXCL6 co-operatively regulate metastasis of colon cancer remain to be clarified.

The purpose of this study was to investigate the co-operative promotion of metastatic potential and the underlying mechanism of CXCL12 and CXCL6 in order to better understand the interaction between colon cancer cells and stromal cells. Furthermore, our study provided data to demonstrate that phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR signaling pathway plays an important role in CXCL12 simulation and that this process is involved in the development and metastasis of colon cancer. Understanding the biologic mechanisms responsible for regulation of chemokines may enable better molecular targeted therapies to treat patients with metastatic colon cancer.

**MATERIALS AND METHODS**

**Reagents and antibodies**

Recombinant human CXCL6 and CXCL12 were purchased from R&D Systems (Minneapolis, MN, United States). Neutralizing monoclonal anti-human CXCL12 (anti-CXCL12 Ab), anti-human CXCL6 (anti-CXCL6 Ab), anti-human CXCR4 (anti-CXCR4 Ab) were obtained from Carbiochem (San Diego, CA, United States).

**Cell lines and culture condition**

The human colon cancer cell lines HT29, WiDr, CaCo-2, DLD-1 and Colo320 were obtained from the American Type Culture Collection (Rockville, MD, United States). DLD-1, WiDr and CaCo-2 were maintained in minimum essential medium (Eagle’s; (Sigma Chemical Co., St. Louis, MO, United States)) with high glucose and 10% fetal bovine serum (FBS). HT-29 and Colo320 were maintained in RPMI-1640 medium (Sigma Chemical Co.) supplemented with 10% FBS. HUVECs were obtained from Kurubo Co. (Osaka, Japan) and maintained in HuMedia-EG2 medium supplemented with 2% FBS, 5 ng/mL basic fibroblast growth factor, 10 µg/mL heparin, 10 ng/mL epidermal growth factor, and 1 µg/mL of hydrocortisone, according to the supplier’s instruction (Kurubo Co.). All cells were incubated at 37°C in a humidified atmosphere of 5% CO\(_2\) in air.

**Western blot analysis**

Cells were cultured in the media supplemented with 1% FBS for 1 d. After the indicated treatments, the cells were lysed in lysis buffer [25 mmol/L Tris (pH 7.8) with H\(_2\)PO\(_4\), 2 mmol/L CDTA, 10 mmol/L DTT, 10% glycerol, 1% Triton X-100, 2 mmol/L PMSF, 1 mmol/L sodium orthovanadate, and 10 µmol/L leupeptin]. The protein concentrations were measured with a BCA protein assay kit (Pierce, Rockford, IL, United States). The amounts of samples were 30 µg per lane. The lysates were separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene membrane (Immobllo PVDF; Nihon Millipore Ltd, Tokyo, Japan). The membrane was incubated in the blocking buffer for 60 min at room temperature. The blocking buffer consisted of 5% nonfat dry milk dissolved into Tris-buffered saline containing 0.1% Tween 20 (TBS-T). After washing the membrane with TBS-T, the membrane was immunoblotted with each primary antibody (Ab) diluted into 1:1000-2000 overnight at 4°C. Afterward, membranes were washed with TBS-T three times, and subjected to HRP-conjugated secondary Ab for 60 min at room temperature. Protein Ab complexes were visualized with an ECL western blotting detection and analysis system (Amersham Biosciences, Buckinghamshire, United Kingdom). β-actin western blots served as controls.

**Enzyme-linked immunosorbent assay**

All cancer cell lines and fibroblasts were separately seeded at a density of 3 × 10\(^3\) cells/mL into 12-well plates containing medium with 10% FBS and allowed to adhere overnight. The medium was exchanged, and cells were cultured for an additional 48 h. The medium was collected and microcentrifuged at 1500 rpm for 5 min to remove particles, and the supernatants were frozen at -80°C until performance of enzyme-linked immunosorbent assay (ELISA). Concentration of CXCL6 was measured by ELISA kit (R&D Systems) according to the manufacturer’s instructions.

In order to further investigate the synergistic effect of the tumor-stromal interaction, we tested the effect of fibroblast-derived CXCL12 on cancer cell CXCL6 production using a double-chamber method in 24-well plates. Fibroblasts were seeded at a density of 1 × 10\(^3\) cells/well into 24-well plates, and allowed to adhere overnight. The medium was exchanged with or without CXCL12 Ab, and then co-cultured with 5 × 10\(^3\) HT-29, WiDr, CaCo-2, DLD-1 and fibroblasts cells that had been placed into inserts with 0.45-mm\(^2\) pores (Kurabo Co.). The co-culture systems were incubated for an additional 48 h, and CXCL6 concentration was subsequently measured as described above. Each condition was assessed using 5 independent samples.

**Proliferation assay**

To confirm the effect of chemokines on HUVEC proliferation, we performed the proliferation assay according to the manufacturer’s instructions. HUVECs were seeded at a density of 5 × 10\(^3\) cells/100 µL in
To further investigate the influence of colon cancer cells in vitro angiogenic activity during co-culture with colon cancer

Invasion assay
The effects of CXCL12, CXCL6 and co-cultures with fibroblasts or colon cancer cells (DLD-1) on invasive capability of HUVECs were determined by Matrigel-coated invasion chambers (Becton Dickinson, Bedford, MA, United States) according to the manufacturer’s instructions. This system is separated by a PET membrane coated with Matrigel Matrix (Becton Dickinson, Bedford, MA, United States) at a test wavelength of 690 nm.

Angiogenesis assay
To investigate the influence of CXCL6 on tubule formation by HUVECs, HUVECs and fibroblasts were co-cultured using a double-chamber method in 24-well plates. The media were exchanged every 2 d, with co-incubation continuing for 24-h incubation, 10 µL WST-1 reagent was added to each well and cells were incubated for another 4 h at 37 °C, then the cell proliferation was measured by the WST-1 Cell Proliferation Assay System (Takara Bio Inc., Shiga, Japan). The absorbance was determined using a microplate reader (Molecular Devices, Sunnyvale, CA, United States) at a test wavelength of 450 nm and reference wavelength of 690 nm.

Effect of CXCL12 on secreted level of CXCL6 from colon cancer cell lines and HUVECs
The secreted CXCL6 level was measured by ELISA assay in colon cancer cell lines and stromal cells. On the basis of this assay, secretion of CXCL6 was higher in DLD-1 and HT-29 cell supernatants than in supernatants from CaCo-2, WiDr and HUVECs. The addition of recombinant CXCL12 significantly enhanced CXCL6 production in CaCo-2 (2.54-fold vs control, P < 0.01; Figure 2A), WiDr (2.07-fold vs control, P < 0.01; Figure 2B), HT-29 (1.87-fold vs control, P < 0.01; Figure 2C) and HUVEC (2.79-fold vs control, P < 0.01; Figure 2D). Likewise, co-culture with fibroblast cells also significantly enhanced CaCo-2 (1.89-fold vs control, P < 0.01), WiDr (1.67-fold vs control, P < 0.01), HT-29 (1.62-fold vs control, P < 0.01) and HUVEC (2.15-fold vs control, P < 0.01) cells’ secretion of CXCL6. On the other hand, recombinant CXCL12 and co-culture with fibroblasts did not promote the CXCL6 secretion in DLD-1 culture supernatants (Figure 2D). Co-culture with DLD-1 cells significant
enlarged CXCL6 secretion level in the HUVEC culture supernatants as well (P < 0.01), because fibroblasts could secrete CXCL12 protein. Furthermore, the enhanced CXCL6 production elicited by co-culturing with fibroblast cells and recombinant CXCL12 were significantly inhibited in the presence of CXCL12 Ab (P < 0.01).

**HUVEC proliferation following treatment with CXCL6, CXCL12 and fibroblast cell-cultured supernatants**

To create stromal cell supernatants, fibroblast cells were seeded to a final number of 5 × 10⁵ cells/5 mL into 100-mm dishes containing medium with 10% FBS, and were cultured overnight. Cells were then cultured in medium containing 2% FBS for 48 h. The culture media were collected and microfuged at 1500 rpm for 5 min to remove any particles, and the supernatants were used in proliferation assays. Recombinant CXCL6 elicited enhanced proliferation of HUVECs in a dose-dependent manner, and co-culture with fibroblasts caused significantly enhanced HUVEC proliferation (P < 0.05, P < 0.01; Figure 3A). Recombinant CXCL6 also promoted the proliferation of HUVECs in a concentration-dependent manner (P < 0.05, P < 0.01; Figure 3B).

**CXCL6 and CXCL12 promotion of colon cancer cell and HUVEC invasiveness**

The invasion assay was used to investigate whether CXCL12 and CXCL6 influence invasiveness of colon cancer cell lines. The invasive capacity of HT-29 cells was promoted by stimulation using recombinant CXCL6 (Figure 4A) and CXCL12 (Figure 4B) in a concentration-dependent manner (P < 0.05, P < 0.01), and 10 ng/mL of CXCL6 and CXCL12 significantly promoted cancer cell invasion (P < 0.01). Interestingly, CXCL6 (Figure 4C) and CXCL12 (Figure 4D) also significantly enhanced the invasion of HUVECS in a dose-dependent manner (P < 0.05, P < 0.01). However, the invasive behavior of HUVECS upon CXCL6 stimulation was more significant than upon CXCL12 stimulation. Enhancement of invasive ability of HUVECS by CXCL6 and CXCL12 stimulation were blocked by pre-incubating HUVECs with neutralizing anti-CXCL6 and anti-CXCL12 Ab, respectively (P < 0.05, P < 0.01; Figure 4C).

**Effect of co-culturing with fibroblasts and DLD-1 cells on HUVEC invasiveness**

To investigate the interaction between colon cancer and stromal cell-derived CXCL12 in the tumor microenvironment, we next examined the role of cell-derived CXCL12 on HUVECs’ invasiveness using the Matrigel double culturing chamber invasion assay. The invasive capability of HUVECs were enhanced by co-cultivation with fibroblasts (P < 0.01; Figure 4E) and DLD-1 (P < 0.01; Figure 4F); meanwhile, the enhancement of HUVEC invasive behavior was inhibited by neutralizing anti-CXCL12 Ab (P < 0.01), and the addition of recombinant CXCL6 significantly enhanced HUVECs invasiveness in co-cultivation with fibroblasts system as well (P < 0.01; Figure 4E). At the same time, co-cultivation with CaCo-2 cells did not significantly increase the invasion of HUVECs.

**CXCL6 and CXCL12 enhancement of tube formation**

To further determine the role of CXCL12 and CXCL6 in the living cell microenvironment, we focused on the interaction between tumor cells and stromal cells by characterizing angiogenic activity in co-cultured fibroblasts and vascular ECs, and the effect of CXCL6 and CXCL12 in this system. Initially, we measured the influence of CXCL6 and CXCL12 on tube formation by HUVECs. HUVEC tube formation was significantly enhanced in a dose-dependent manner following treatment CXCL6 (P < 0.01; Figure 5A) and CXCL12 (P < 0.01; Figure 5B). The enhanced angiogenesis of HUVECS was inhibited by the addition of neutralizing anti-CXCL6 and anti-CXCL12 Ab (P < 0.01).

**Effect of colon cancer cells with or without CXCL12 on tube formation by HUVECs**

In order to explore the different secreted CXCL2 of colon cancer cells influence on tube formation by HUVECs, we cultured three cell lines using double chamber methods to determine the interaction among them. The tubular formation was significantly enhanced by co-culture with DLD-1 cells compared with control (HUVECs and fibroblasts only) or co-culture with HT-29 and CaCo-2 cells, respectively (P < 0.01; Figure 5C). Moreover, the CXCL12 and CXCL6 could significantly promote the tubular formation in co-culture with HT-29 and CaCo-2 cells system (P < 0.01). In contrast, the enhanced tubular formation by HUVECs was significantly inhibited by addition of anti
The alteration of HUVECs were cultured in medium containing different concentrations of CXCL6 (A), CXCL12 (B) and conditioned medium from fibroblasts. After 72 h of incubation, HUVEC proliferation was assessed using premixed WST-1 cell proliferation assay (column mean absorbance reading; Bars = SD). Multiple comparisons were performed by one-way ANOVA followed by the SNK test; $^aP < 0.05$, $^bP < 0.01$. CXCL6: Granulocyte chemotactic protein-2; CXCL12: Stromal cell-derived factor-1; HUVEC: Human umbilical vein endothelial cell.

**Figure 2** Enhancement of secreted granulocyte chemotactic protein-2 levels in colon cancer cell lines and stromal cells by recombinant stromal cell-derived factor-1 and co-culture with fibroblasts. The alteration of CXCL6 secretion from colon cancer cell lines (CaCo-2 (A), WiDr (B), HT-29 (C) and DLD-1 (D)) by recombinant CXCL12 stimulation or co-culture with fibroblasts (FB) were determined by enzyme-linked immunosorbent assay in cell culture medium. Meanwhile, colon cancer cells were treated with anti-CXCL12 antibody (Ab) for 2 h, and the concentration of CXCL6 was measured by ELISA in supernatants from colon cancer cells. Effect on secretion of CXCL6 from HUVECs stimulated by recombinant CXCL12 in co-culture system with fibroblasts and the colon cancer cells DLD-1 are shown (E). The experimental detail is described in the “Materials and Methods” section. Control: colon cancer cells only; FB: fibroblasts only; CXCL12: treated with recombinant CXCL12; with FB: colon cancer cells co-cultured with fibroblasts; with FB + Ab: colon cancer cells co-cultured with fibroblasts and pre-treated with anti-CXCL12 Ab. The values are expressed as mean ± SD. Ab: Antibody; CXCL6: Granulocyte chemotactic protein-2; CXCL12: Stromal cell-derived factor-1; HUVEC: Human umbilical vein endothelial cell.

**Figure 3** Effect of stromal cell-derived factor-1, granulocyte chemotactic protein-2 and conditioned medium from fibroblasts on human umbilical vein endothelial cell proliferation. HUVECs were cultured in medium containing different concentrations of CXCL6 (A), CXCL12 (B) and conditioned medium from fibroblasts. After 72 h of incubation, HUVEC proliferation was assessed using premixed WST-1 cell proliferation assay (column mean absorbance reading; Bars = SD). Multiple comparisons were performed by one-way ANOVA followed by the SNK test; $^aP < 0.05$, $^bP < 0.01$. CXCL6: Granulocyte chemotactic protein-2; CXCL12: Stromal cell-derived factor-1; HUVEC: Human umbilical vein endothelial cell.

**CXCL12 Ab in co-culture with DLD-1 cells ($P < 0.01$).**

**Activation of the PI3K/Akt/mTOR signaling pathway after CXCL12 stimulation in colon cancer and stromal cells**

We used the colon cancer cell HT-29 and stromal cell HUVECs to examine activation of the PI3K/Akt/mTOR signaling pathway, a downstream target of CXCL12. The stimulation by 10 ng/mL of CXCL12 could increase Akt (Figure 6A), PI3K (Figure 6B) and mTOR (Figure 6C) phosphorylation in a time-dependent manner in HT-29 cells and HUVECs. To determine the role of mTOR, we investigated the effect of CXCL12 and PI3K/Akt inhibitor on the activation of mTOR in colon cancer cells and HUVECs; we looked at the effects of IGF-1 and/or PI3/Akt kinase inhibitors on the activation of mTOR in these cells. HT-29 and HUVECs were pre-treated for 60 min with PI3/Akt inhibitors and then stimulated overnight with CXCL12 (100 ng/mL). The extracted proteins were separated by SDS-PAGE, transferred to membranes, and the membranes probed with Ab directed against phospho-mTOR and total mTOR. We found that by CXCL12-mediated increase phospho-mTOR was inhibited by 50 μmol/L PI3K inhibitor (LY294002) and 50 μmol/L Akt kinase inhibitor. These data indicate that CXCL12 regulates the PI3K/Akt/mTOR signaling pathway activity and...
Ma JC et al. CXCL12- and CXCL6-enhanced metastatic potential in colon carcinoma

**A**

![Graph showing CXCL6 effects on cell invasion percentage](image)

**B**

![Graph showing CXCL12 effects on cell invasion percentage](image)

**C**

![Graph showing CXCL6 and CXCL12 effects on cell invasion percentage](image)

**D**

![Graph showing CXCL6 and CXCL12 effects on cell invasion percentage](image)
suggest that the PI3K/Akt/mTOR signaling pathway could participate in the regulation of metastatic behavior by colon cancer cells (Figure 6D).

**DISCUSSION**

Many tumors produce chemokines, which may explain the presence of the tumor-associated microenvironment. However, the role of these chemokines in tumor biology is still unclear. Chemokines form a complex family of small, secreted proteins that play important roles in innate and adaptive immunity, homeostatic processes, angiogenesis and tumorigenesis\(^1\). Recent exploration of the tumor microenvironment has become the crux of research aimed at explaining tumor behaviors, especially those involving metastasis of solid tumors as in colon, stomach, liver, lung and breast cancers.

The tumor microenvironment consists of tumor, stromal, immune and inflammatory cells, all of which produce cytokines, growth factors and adhesion molecules\(^{2,21}\), and the abnormal expression of cytokines has been shown to have great effect on tumor behaviors, such as tumor progression and metastasis\(^{28,29}\). The CXC chemokine family of cytokines, which are founded in the microenvironment, represent a significant difference between tumors and normal tissues\(^{30}\). The tumor microenvironment contains secreted chemokines representing distinctive profiles, the components of each having specific target cells. The chemokine CXCL12, through its receptor CXCR4, positively regulates angiogenesis by promoting EC migration and tube formation. However, the relevant downstream signaling pathways in EC have not been defined.

Our previous studies elucidated that IL-1\(\alpha\) is one of the most important inflammatory cytokines involved in the metastatic process of colon cancer. IL-1\(\alpha\) contributed to the regulation of tumor growth, progression, and liver metastasis in primary gastric carcinoma and pancreatic cancer. Pancreatic cancer cell-derived IL-1\(\alpha\) increases fibroblast-derived hepatocyte growth factor (HGF) secretion in a paracrine manner, and that enhanced HGF expression promotes invasion, proliferation and angiogenesis of cancer cells. In the living microenvironment of the tumor, the chemokines act as couriers or guides for promoting tumor development and the metastasis process\(^{31-33}\).
The treatment of CXCL6 or anti-CXCL12 Ab, the co-culture for 7 d, the HUVEC/fibroblast co-culture system was stained with anti-CD31 antibody. Tube formation area was measured quantitatively using an image analyzer. A1: Control; A2: 1 ng/mL of CXCL6; A3: 10 ng/mL CXCL6; A4: 10 ng/mL CXCL6 + 10 µg/mL of CXCL6 Ab. B1: Control; B2: 1 ng/mL CXCL12; B3: 10 ng/mL CXCL12; B4: 10 ng/mL CXCL12 + 10 µg/mL of CXCL12 Ab. Effect of colon cancer cells (DLD-1, HT-29 or CaCo-2) on HUVEC tube formation is shown (C). Angiogenesis assay by HUVEC/fibroblast co-culture with DLD-1, HT-29 or CaCo-2 cells was conducted using the double-chamber method. Detection of tube formation by HUVECs was described in the “Material and Methods” section. C1: Co-culture with DLD-1; C2: Co-culture with DLD-1 + 10 ng/mL of CXCL6; C3: Co-culture with DLD-1 + 10 ng/mL of CXCL12; C4: Co-culture with DLD-1 + 10 µg/mL of CXCL12 Ab; C5: Co-culture with HT-29 cells; C6: Co-culture with HT-29 cells pre-treated with 10 ng/mL CXCL6; C7: Co-culture with HT-29 cells pre-treated with 10 ng/mL CXCL12; C8: Co-culture with HT-29 + 10 µg/mL of CXCL12 Ab; C9: Co-culture with CaCo-2 cells; C10: Co-culture with CaCo-2 cells pre-treated with 10 ng/mL CXCL6; C11: Co-culture with CaCo-2 cells pre-treated with 10 ng/mL CXCL12; C12: Co-culture with CaCo-2 cells pre-treated with 10 µg/mL anti-CXCL12 antibody. Columns, mean pixels of HUVEC tube formation area; Bars = SD. Multiple comparisons were performed by one-way ANOVA followed by the SNK test; *P < 0.01 vs control. Ab: Antibody; CXCL6: Granulocyte chemotactic protein-2; CXCL12: Stromal cell-derived factor-1; HUVEC: Human umbilical vein endothelial cell.

As a structural component of tumor tissue, fibroblasts have been shown to be deeply involved in tumor proliferation and the mitogenic processes. Fibroblasts produce certain cytokines that influence neighboring cells, including malignant cells[4]. The precise role of chemokines in neovascularization during inflammation or tumor growth is not yet fully understood. We investigated here whether cancer cell stromal cell-derived CXCL12 influences colon cancer CXCL6 secretion, thereby co-regulating the metastatic potential of colon cancer. Our results revealed that CXCL12 was expressed in DLD-1 and fibroblasts, while CXCL6 and CXCR4 were expressed in all cell lines.

The most salient observations of our study were that the secreted CXCL6 levels by colon cancer cells and HUVECs were significantly promoted by cancer cell (DLD-1)- and stromal cell (fibroblast)-derived CXCL12 in the co-culturing system, and that the enhanced CXCL6 production could be significantly inhibited by CXCL12 Ab. Similar results were reported for other effects through the up-regulation of MMP-9, providing a possible mechanism mediating the effect of CXCL6 on metastasis[34]. In our study, CXCL6 and CXCL12 not only co-operatively enhanced proliferation and invasion of HUVECs, but also promoted the invasion of colon cancer cells. Similarly, CXCL6 has been reported to be up-regulated in colon cancer, and plays key roles in the induction and maintenance of gut inflammation, enhancing the development and growth of colitis-associated colorectal cancer[35].

To further investigate the interaction between CXC chemokines and cancer cell living microenvironment, we focused on the interaction between tumor cells and stromal cells by characterizing angiogenic activity in co-cultured fibroblasts and vascular ECs, and the effect of CXCL6 and CXCL12 in this system. HUVEC tube formation was significantly enhanced by CXCL6. We aimed to explore the influence of different secreted CXCL2 from colon cancer cells on tube formation by HUVECs. The tubular formation was significantly enhanced by co-culture with DLD-1 cells, as compared with colon cancer cells, and this is related to the produced CXCL12. In contrast, the enhanced tubular formation by HUVECs was significantly inhibited by...
addition of anti-CXCL12 Ab in co-culture with DLD-1 cells (Figure 5). CXCL12 should be the initial factor secreted by fibroblasts, and the target colon cancer cells enhanced the secretion of CXCL6 after CXCL12 combined with its receptor CXCR4. The proliferation and invasion of colon cancer cells and HUVECs have been activated and enhanced after a series of complicated biochemical reactions.

Breakthroughs of insights into the tumor micro-environment have made great contributions towards clinical treatment. All kinds of anti-carcinoma chemotherapeutics have been based upon this mechanism, and there is no exception among the newly targeted cancer therapies or the gene therapies; proof of effects for colon cancer cells to metastasize.

Crosstalk between CXCR4, CXCL12 and PI3K/mTOR has been previously described in peritoneal disseminated gastric cancer and pancreatic cancer. The solid tumors indicate an interconnection between CXCL12 and mTOR signaling. Interfering with mTOR signaling has abolished chemotaxis towards CXCL12[38]. The mTOR will enhance cell growth and proliferation via promotion of the ribosome S6 protein kinase (p70S6K) and inhibition of the eIF4E-binding proteins (4E-BP1), and can even enhance the secretion of vascular endothelial growth factor and angiogenesis by promoting expression of the transcription factor hypoxia-inducible factor 1 and its downstream target genes. Under a series of exterior and interior factors, cancer cell proliferation and invasion can be induced and cell apoptosis can be avoided by initiating the PI3K/Akt/mTOR pathway[39].

In conclusion, this is the first report on the concomitant involvement of CXCL12 and CXCL6 both transducing the mTOR pathway, affecting progression and spreading of human colon cancer cells, ultimately suggesting that targeting of CXCR4 and mTOR may improve therapeutic efficacy and prevent mTOR-targeting agents’ resistance. Our work should encourage further investigation into more potent angiogenesis modulating agents to improve the effectiveness of colon cancer therapies.

COMMENTS

Background
Colon cancer is the fourth most frequently diagnosed cancer worldwide. The poor prognosis of colon cancer is attributable to its tendency of metastases.
However, the precise mechanisms of metastasis are still unknown. The target of this study was to investigate the underlying mechanism by which CXCL12 and CXCL6 influences the metastatic potential of colon cancer and the internal relation of colon cancer and stromal cell, as well as to investigate the interaction with CXCL12/CXCL6/P38/PI3K/Akt/mTOR signaling in the metastatic process.

Research frontiers

The functions of CXC chemokines in the tumor microenvironment depend considerably on the chemokine type and tumor and stromal cell characteristics. Both the angiogenesis-promoting effect of CXCL12 and chemotactic effect of CXCL12 play important roles in tumorigenesis and metastasis. However, the molecular mechanisms of the activity signaling pathway by which CXCL12 and CXCL6 co-operatively regulate metastasis of colon cancer remain to be clarified.

Innovations and breakthroughs

This research provides the first demonstrations of fibroblast-derived CXCL12 enhancing CXCL6 secretion of colon cancer cells. CXCL6 and CXCL12 not only co-operative enhanced proliferation and invasion of HEUVECs, but also promoted the invasion of colon cancer cells via the P38/PI3K/Akt/mTOR signaling pathway. Blocking this pathway may be a potential anti-metastatic therapeutic target for patients with colon cancer. This work might encourage further investigation into more potent angiogenesis modulating agents to improve the effectiveness of colon cancer therapies.

Applications

The concomitant involvement of CXCL12 and CXCL6 transduces the mTOR pathway, affecting progression and spread of human colon cancer cells. The authors suggest that targeting CXCR4 and mTOR may improve therapeutic efficacy and prevent mTOR-targeting agents’ resistance. The authors’ work should encourage further investigation into more potent angiogenesis modulating agents to improve the effectiveness of colon cancer therapies.

Terminology

The CXC chemokine family of cytokines, found in the microenvironment, represent the significantly distinctive profiles of tumors and normal tissues. The tumor microenvironment contains secreted chemokines representing distinctive profiles, the components of each having specific target cells. The chemokine CXCL12, through its receptor CXCR4, positively regulates angiogenesis by promoting endothelial cell (EC) migration and tube formation.

Peer-review

The results of this study for the relationship between CXCL6 and CXCL12 in colorectal cancer and ECs seem to be of interest to many readers, and the experiment is well planned. But, before publication, several issues have to be considered.

REFERENCES

1. Siegel RL, Fedewa SA, Miller KD, Goding Sauer A, Pinheiro PS, Martin-Tyson D, Jemal A. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin 2015; 65: 457-480 [PMID: 26375877 DOI: 10.3322/caac.21314]

2. Cotte E, Villeneuve L, Passot G, Boschetti G, Bin-Dorel S, Francois Y, Glehen O; French Research Group of Rectal Cancer Surgery (GRECCAR). GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unrespectable synchronous metastasis: a randomized multicentre study. BMC Cancer 2015; 15: 47 [PMID: 25849254 DOI: 10.1186/s12885-015-0600-0]

3. Kim GR, Ha GH, Bae JH, Oh SO, Kim SH, Kang CD. Metastatic colon cancer cell populations contain more cancer stem-like cells with a higher susceptibility to natural killer cell-mediated lysis compared with primary colon cancer cells. Oncol Lett 2015; 9: 1641-1646 [PMID: 25789015 DOI: 10.3892/ol.2015.2918]

4. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokine grammar for immune cells. Annu Rev Immunol 2004; 22: 891-928 [PMID: 15302599 DOI: 10.1146/annurev.immunol.22.012703.104543]

5. Baggioioli M. Chemokines in pathology and medicine. J Intern Med 2001; 250: 91-104 [PMID: 11489059 DOI: 10.1046/j.1365-2796.2001.00867.x]

6. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-127 [PMID: 10714678 DOI: 10.1016/S1074-7613(00)00165-X]

7. Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007; 256: 137-165 [PMID: 17629396 DOI: 10.1016/j.canlet.2007.05.013]

8. Zlotnik A. Chemokines and cancer. Int J Cancer 2006; 119: 2026-2029 [PMID: 16671092 DOI: 10.1002/ijc.22024]

9. Lazennec G, Richard A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010; 16: 133-144 [PMID: 20163989 DOI: 10.1016/j.molmed.2010.01.003]

10. Ben-Barouch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 2006; 25: 357-371 [PMID: 17016763 DOI: 10.1007/s10555-006-9003-5]

11. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540-550 [PMID: 15229479 DOI: 10.1038/nrc1388]

12. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naemn C, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348 [PMID: 15882617 DOI: 10.1016/j.cell.2005.02.034]

13. Molyneaux KA, Zinszner H, Kunwar PS, Schaible K, Stebler J, Sunshine MJ, O’Brien W, Raz E, Littman D, Wylie C, Lehnmann R. The chemokine SDF1/CXCL12 and its receptor CXCR4 regulate mouse germ cell migration and survival. Development 2003; 130: 4279-4286 [PMID: 12900445 DOI: 10.1242/dev.00630]

14. Latallade JJ, Clay D, Bourin P, Hérodin F, Dupuy C, Jasmin C, Le Bousse-Kerdilès MC. Stromal cell-derived factor-1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G(0)/G(1) transition in CD34(+) cells: evidence for an autocrine/paracrine mechanism. Blood 2002; 99: 1117-1129 [PMID: 11830456 DOI: 10.1182/blood.V99.4.1117]

15. Burger JA, Tsukada N, Burger M, Zvaifler NJ, D’Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000; 96: 2655-2663 [PMID: 11025495]

16. Zheng K, Li HY, Su XL, Wang XY, Tian T, Li F, Ren GS. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2010; 29: 31 [PMID: 20380740 DOI: 10.1186/1374-5276-29-31]

17. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56 [PMID: 11242036 DOI: 10.1038/35050516]

18. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16: 2927-2931 [PMID: 20840421 DOI: 10.1158/1078-0432.CCR-09-2329]

19. Ohtani H, Jin Z, Takegawa S, Nakayama T, Yoshie O. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells present in invasive human breast carcinomas. J Exp Clin Cancer Res 2011; 30: 51 [PMID: 21380740 DOI: 10.1186/1756-9966-29-31]

20. Costantini S, Romano G, Rusolo F, Capone F, Guerriero E, Colonna G, Ianora A, Ciliberto G, Costantini M. Anti-Inflammatory Effects of a Methanol Extract from the Marine Sponge Geodia cydonium on the Human Breast Cancer MCF-7 Cell Line. Mediators Inflamm 2015; 2015: 204975 [PMID: 26491222 DOI: 10.1155/2015/204975]

21. Dakkevienc E, Jonuviene V, Zitkute V, Zalyte E, Grigaitis P, Kirveliene V, Snauskaiene A. The role of interleukin-8 (CXCL8)
Ma JC et al. CXCL12- and CXCL6-enhanced metastatic potential in colon carcinoma

and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116. *Med Oncol* 2015; 32: 258 [PMID: 26519257 DOI: 10.1007/s12052-015-0703-y]

**Kucia M**, Reca R, Miekus K, Wanecek J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. Trafficking of normal stem cells and metastasis of cancer stem cells involves similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. *Stem Cells* 2005; 23: 879-894 [PMID: 15888687 DOI: 10.1634/stemcells.2004-0342]

**Ben-Baruch** A. Site-specific metastasis formation: chemokines as regulators of tumor cell adhesion, motility and invasion. *Cell Adh Migr* 2009; 3: 328-333 [PMID: 19550136]

**Staiano RJ**, Loffredo S, Borriello F, Iannotti FA, Piscitelli F, Orlando P, Secondo A, Granata F, Lepore MT, Fiorelli A, Varricchi G, Santini M, Triggiani M, Di Marzo V, Marone G. Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. *J Leukoc Biol* 2016; 99: 531-540 [PMID: 26467187 DOI: 10.1189/jlb.3HI1214-584R]

**Coperchini** F, Pignatti P, Leporati P, Carbone A, Croce L, Magri F, Chiovato L, Rotondi M. Normal human thyroid cells, BCPAP, Coperchini F, Chiovato L, Rotondi M. Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both factors. *FASEB J* 2012. 03. 017
direct therapy in pancreatic cancer. *M. Stromal cell-derived factor 1α mediates resistance to mTOR-C driven therapy in pancreatic cancer. *JNCI 2012. 1056-1068 [PMID: 25466898 DOI: 10.1096/fj.14-260083]

**Kucia M**, Reca R, Miekus K, Wanecek J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. Trafficking of normal stem cells and metastasis of cancer stem cells involves similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. *Stem Cells* 2005; 23: 879-894 [PMID: 15888687 DOI: 10.1634/stemcells.2004-0342]

**Ben-Baruch** A. Site-specific metastasis formation: chemokines as regulators of tumor cell adhesion, motility and invasion. *Cell Adh Migr* 2009; 3: 328-333 [PMID: 19550136]

**Staiano RJ**, Loffredo S, Borriello F, Iannotti FA, Piscitelli F, Orlando P, Secondo A, Granata F, Lepore MT, Fiorelli A, Varricchi G, Santini M, Triggiani M, Di Marzo V, Marone G. Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. *J Leukoc Biol* 2016; 99: 531-540 [PMID: 26467187 DOI: 10.1189/jlb.3HI1214-584R]

**Coperchini** F, Pignatti P, Leporati P, Carbone A, Croce L, Magri F, Chiovato L, Rotondi M. Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both factors. *FASEB J* 2012. 03. 017

direct therapy in pancreatic cancer. *M. Stromal cell-derived factor 1α mediates resistance to mTOR-C driven therapy in pancreatic cancer. *JNCI 2012. 1056-1068 [PMID: 25466898 DOI: 10.1096/fj.14-260083]

**Kucia M**, Reca R, Miekus K, Wanecek J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. Trafficking of normal stem cells and metastasis of cancer stem cells involves similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. *Stem Cells* 2005; 23: 879-894 [PMID: 15888687 DOI: 10.1634/stemcells.2004-0342]

**Ben-Baruch** A. Site-specific metastasis formation: chemokines as regulators of tumor cell adhesion, motility and invasion. *Cell Adh Migr* 2009; 3: 328-333 [PMID: 19550136]

**Staiano RJ**, Loffredo S, Borriello F, Iannotti FA, Piscitelli F, Orlando P, Secondo A, Granata F, Lepore MT, Fiorelli A, Varricchi G, Santini M, Triggiani M, Di Marzo V, Marone G. Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. *J Leukoc Biol* 2016; 99: 531-540 [PMID: 26467187 DOI: 10.1189/jlb.3HI1214-584R]

**Coperchini** F, Pignatti P, Leporati P, Carbone A, Croce L, Magri F, Chiovato L, Rotondi M. Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both factors. *FASEB J* 2012. 03. 017

direct therapy in pancreatic cancer. *M. Stromal cell-derived factor 1α mediates resistance to mTOR-C driven therapy in pancreatic cancer. *JNCI 2012. 1056-1068 [PMID: 25466898 DOI: 10.1096/fj.14-260083]

**Kucia M**, Reca R, Miekus K, Wanecek J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. Trafficking of normal stem cells and metastasis of cancer stem cells involves similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. *Stem Cells* 2005; 23: 879-894 [PMID: 15888687 DOI: 10.1634/stemcells.2004-0342]

**Ben-Baruch** A. Site-specific metastasis formation: chemokines as regulators of tumor cell adhesion, motility and invasion. *Cell Adh Migr* 2009; 3: 328-333 [PMID: 19550136]

**Staiano RJ**, Loffredo S, Borriello F, Iannotti FA, Piscitelli F, Orlando P, Secondo A, Granata F, Lepore MT, Fiorelli A, Varricchi G, Santini M, Triggiani M, Di Marzo V, Marone G. Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. *J Leukoc Biol* 2016; 99: 531-540 [PMID: 26467187 DOI: 10.1189/jlb.3HI1214-584R]

**Coperchini** F, Pignatti P, Leporati P, Carbone A, Croce L, Magri F, Chiovato L, Rotondi M. Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both factors. *FASEB J* 2012. 03. 017

direct therapy in pancreatic cancer. *M. Stromal cell-derived factor 1α mediates resistance to mTOR-C driven therapy in pancreatic cancer. *JNCI 2012. 1056-1068 [PMID: 25466898 DOI: 10.1096/fj.14-260083]

**Kucia M**, Reca R, Miekus K, Wanecek J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. Trafficking of normal stem cells and metastasis of cancer stem cells involves similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. *Stem Cells* 2005; 23: 879-894 [PMID: 15888687 DOI: 10.1634/stemcells.2004-0342]

**Ben-Baruch** A. Site-specific metastasis formation: chemokines as regulators of tumor cell adhesion, motility and invasion. *Cell Adh Migr* 2009; 3: 328-333 [PMID: 19550136]

**Staiano RJ**, Loffredo S, Borriello F, Iannotti FA, Piscitelli F, Orlando P, Secondo A, Granata F, Lepore MT, Fiorelli A, Varricchi G, Santini M, Triggiani M, Di Marzo V, Marone G. Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. *J Leukoc Biol* 2016; 99: 531-540 [PMID: 26467187 DOI: 10.1189/jlb.3HI1214-584R]

**Coperchini** F, Pignatti P, Leporati P, Carbone A, Croce L, Magri F, Chiovato L, Rotondi M. Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both factors. *FASEB J* 2012. 03. 017

direct therapy in pancreatic cancer. *M. Stromal cell-derived factor 1α mediates resistance to mTOR-C driven therapy in pancreatic cancer. *JNCI 2012. 1056-1068 [PMID: 25466898 DOI: 10.1096/fj.14-260083]
